Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
12 competitors in Non-small Cell Lung Cancer
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tepmetko
Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
View on EMADiabetic Retinopathy
Osteoporosis
Cardiovascular Disease
Malignant Neoplasms of Male Genital Organs
HPV Positive Oropharyngeal Squamous Cell Carcinoma